Recombinant multi-species PSME3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine PSME3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The 26S proteasome is a multicatalytic proteinase complex with a highly ordered structure composed of 2 complexes, a 20S core and a 19S regulator. The 20S core is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. The 19S regulator is composed of a base, which contains 6 ATPase subunits and 2 non-ATPase subunits, and a lid, which contains up to 10 non-ATPase subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. The immunoproteasome contains an alternate regulator, referred to as the 11S regulator or PA28, that replaces the 19S regulator. Three subunits (alpha, beta and gamma) of the 11S regulator have been identified. This gene encodes the gamma subunit of the 11S regulator. Six gamma subunits combine to form a homohexameric ring. Alternate splicing results in multiple transcript variants. [provided by RefSeq, May 2012]
The Alternative Names of target: 11S regulator complex subunit gamma (REG-gamma),Ab2-371,Activator of multicatalytic protease subunit 3,HEL-S-283,Ki,Ki nuclear autoantigen,PA28-gamma,PA28G,PA28gamma,PA28gamma),PSME3,Proteasome activator 28 subunit gamma (PA28g,Proteasome activator complex subunit 3,Psme3,REG-GAMMA,REGgamma,pa28g
Go
to PSME3 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP3358-Ag-1/ GM-Tg-hg-IP3358-Ag-2 | Human PSME3 protein | Human |
| GM-Tg-rg-IP3358-Ag-1/ GM-Tg-rg-IP3358-Ag-2 | Rat PSME3 protein | Rat |
| GM-Tg-mg-IP3358-Ag-1/ GM-Tg-mg-IP3358-Ag-2 | Mouse PSME3 protein | Mouse |
| GM-Tg-cynog-IP3358-Ag-1/ GM-Tg-cynog-IP3358-Ag-2 | Cynomolgus/Rhesus macaque PSME3 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP3358-Ag-1/ GM-Tg-felg-IP3358-Ag-2 | Feline PSME3 protein | Feline |
| GM-Tg-cang-IP3358-Ag-1/ GM-Tg-cang-IP3358-Ag-2 | Canine PSME3 protein | Canine |
| GM-Tg-bovg-IP3358-Ag-1/ GM-Tg-bovg-IP3358-Ag-2 | Bovine PSME3 protein | Bovine |
| GM-Tg-equg-IP3358-Ag-1/ GM-Tg-equg-IP3358-Ag-2 | Equine PSME3 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP3358-Ag-1/ GM-Tg-hg-IP3358-Ag-2;
GM-Tg-rg-IP3358-Ag-1/ GM-Tg-rg-IP3358-Ag-2;
GM-Tg-mg-IP3358-Ag-1/ GM-Tg-mg-IP3358-Ag-2; GM-Tg-cynog-IP3358-Ag-1/ GM-Tg-cynog-IP3358-Ag-2; GM-Tg-felg-IP3358-Ag-1/ GM-Tg-felg-IP3358-Ag-2; GM-Tg-cang-IP3358-Ag-1/ GM-Tg-cang-IP3358-Ag-2; GM-Tg-bovg-IP3358-Ag-1/ GM-Tg-bovg-IP3358-Ag-2; GM-Tg-equg-IP3358-Ag-1/ GM-Tg-equg-IP3358-Ag-2 |
| Products Name | PSME3 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | PSME3 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine PSME3 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.